{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "08014B VTE risk assessment  thrombophylaxis in maternity 6.2.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "VENOUS THROMBOEMBOLISM (VTE) RISK ASSESSMENT AND THROMBOPROPHYLAXIS IN MATERNITY"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "08014B"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "6.1"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP/CCP)"
                    },
                    {
                        "text": "Guideline"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "ALL MEHT staff, Midwives, Obstetricians, Paediatricians"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "22 August 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "21 August 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Intrapartum NICE Guidelines RCOG guideline No. 37a April 2015"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "9, 12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Women's and Children's"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Anita Dutta, Consultant for Obstetrics and Gynaecology"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2610 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2612 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "n/a"
                    },
                    {
                        "text": "n/a"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Miss Rao, Lead Consultant for Obstetrics and Gynaecology"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Document Ratification Group"
                    },
                    {
                        "text": "26 June 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group)"
                    },
                    {
                        "text": "July 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "\u2612Trust Intranet \u2612Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "08014B VTE risk assessment  thrombophylaxis in maternity 6.2.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With: this must include Pharmacy if the document has any reference to medication"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Anita Rao"
                    },
                    {
                        "text": "Clinical Director for Women's and Children's Directorate"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Alison Cuthbertson"
                    },
                    {
                        "text": "Head of Midwifery/ Nursing"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Madhu Joshi"
                    },
                    {
                        "text": "Consultant for Obstetrics and Gynaecology"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Angela Woolfenden"
                    },
                    {
                        "text": "Lead Midwife Community"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Amanda Dixon"
                    },
                    {
                        "text": "Lead Midwife Acute Inpatient Services"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Chris Berner"
                    },
                    {
                        "text": "Lead Midwife Clinical Governance"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Claire Fitzgerald"
                    },
                    {
                        "text": "Pharmacist"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Deborah Lepley"
                    },
                    {
                        "text": "Warner Library"
                    },
                    {
                        "text": "24 June 2019"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "(Refer to the main body of the text) 04071 Standard Infection Prevention 04072 Hand Hygiene 06036 Maternity Record Keeping including Documentation in Handheld Records 08033 Thromboprophylaxis and treatment during labour and delivery including caesarean section 12007 Management of women with venous thromboembolism (VTE), deep vein thrombosis (DVT) or pulmonary embolism (PE) during antenatal and postnatal period 05092 Pregnant patient with raised body mass index (BMI) 08079 Clinical audit strategy and policy"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 13,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Nina Smethurst"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "July 2003"
                    },
                    {
                        "text": "2.0"
                    },
                    {
                        "text": "Julie Bishop"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "July 2006"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Sajida Ajjawi"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "March 2008"
                    },
                    {
                        "text": "3.1"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Equality and Diversity; Audit and monitoring update; Update 6.0, 5.4"
                    },
                    {
                        "text": "December 2010"
                    },
                    {
                        "text": "4.0"
                    },
                    {
                        "text": "Dr T T Wai"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "October 2012"
                    },
                    {
                        "text": "4.1"
                    },
                    {
                        "text": "Sarah Moon"
                    },
                    {
                        "text": "Clarification to Appendix F"
                    },
                    {
                        "text": "December 2012"
                    },
                    {
                        "text": "5.0"
                    },
                    {
                        "text": "Dr Richard Haines"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "07 June 2016"
                    },
                    {
                        "text": "5.1"
                    },
                    {
                        "text": "Sarah Moon"
                    },
                    {
                        "text": "Clarification to tables 5.6 and 6.5"
                    },
                    {
                        "text": "12 May 2017"
                    },
                    {
                        "text": "6.0"
                    },
                    {
                        "text": "Anita Dutta"
                    },
                    {
                        "text": "Full Review"
                    },
                    {
                        "text": "22 August 2019"
                    },
                    {
                        "text": "6.1"
                    },
                    {
                        "text": "Miss Kausar"
                    },
                    {
                        "text": "Clarification to 2.0, 5.23, 5.24, 6.3, 6.5, 6.6"
                    },
                    {
                        "text": "03 August 2020"
                    },
                    {
                        "text": "6.2"
                    },
                    {
                        "text": "Rachel Smith"
                    },
                    {
                        "text": "Amendment to appendix F for VTE Risk assessment change to \u201cage 35 years and older\u201d following action plan from SI"
                    },
                    {
                        "text": "02 March 2021"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Purpose ....................................................................................................................... 4 2 Equality Impact Assessment ..................................................................................... 4 3 Background ................................................................................................................. 4 4 Role & Responsibilities within the Trust .................................................................. 4 5 Recommendations ...................................................................................................... 5 6 Antenatal VTE Risk Assessment and Management ................................................. 7 7 Postnatal VTE Risk Assessment and Management ............................................... 10 8 Staff and Training ..................................................................................................... 13 9 Professional Midwifery Advocate ............................................................................ 13 10 Infection Prevention ................................................................................................. 13 11 Audit and Monitoring.................................................................................................13 12 Approval and Implementation ..................................................................................14 13 References .................................................................................................................14 Appendix A: Low Molecular Weight Heparin ................................................................. 15 Appendix B: Antenatal and Postnatal Prophylactic Dose of LMWH ............................ 16 Appendix C: Unfractionated Heparin..............................................................................17 Appendix D: Graduated Elastic Compression Stockings.............................................18"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "text": "Appendix E: Assessment of Bleeding Risk...................................................................19 Appendix F: Obstetric Thromboprophylaxis Risk Assessment and Management....20"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "text": "Appendix G: Obstetric Thromboprophylaxis Risk Assessment and Management: Including early pregnancy complications in Gynaecological Ward............................23"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "text": "Appendix H: Preliminary Equality Ananlysis.................................................................24"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This guideline is designed to help maternity staff to identify, counsel and put the women who need antenatal and postpartum thromboprophylaxis on the correct pathway of care. (Refer to the guideline entitled \u2018Thromboprophylaxis and treatment during labour and delivery including caesarean section'; register number 08033 and \u2018Management of Venous Thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) during antenatal and postnatal period'; register number 12007)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "Mid and South Essex NHS Foundation Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix H)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "A significant fall in maternal death due to VTE followed the publication of the RCOG guideline \u2018Thromboprophylaxis' in 2004. It is likely that the fall in deaths is the result of better recognition of at-risk women and widespread thromboprophylaxis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "The overall incidence of VTE in pregnancy and the puerperium was 1\u20132/ 1000. The case fatality rate of pulmonary embolism was 3.5%. According to the UK Obstetric Surveillance System cohort, 70 % (no 143) of fatal and nonfatal antenatal pulmonary embolisms also had identifiable risk factors."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 3.3,
                "text": "Many antenatal VTE events occur in the first trimester and therefore, if a decision is made to initiate antenatal thromboprophylaxis, this should begin as early in pregnancy as practical."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 3.4,
                "text": "The postpartum period is the highest risk period for VTE, and five times higher in postpartum compared with pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 3.5,
                "text": "The Trust wide audit of VTE prophylaxis is mandatory. This is part of Commissioning for Quality and Innovation (CQUIN) target contract 2010; which states that 90% of patients admitted have to be risk assessed on admission and within 24 hours and of patients assessed as being high risk, 100% have to receive appropriate thromboprophylaxis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles and Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "The Specialist Nurse for Guidelines and Audit is responsible for ensuring clinical policies, guidelines and SOPs, are evidence-based and developed in line with national guidelines and following appropriate consultation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The clinical director is responsible for the implementation of this guideline within the directorate"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "The Head of Midwifery, maternity matrons and maternity managers are responsible for ensuring maternity staff are aware of the guideline and implement it."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "The Obstetric Clinical Lead Consultant and Labour Ward Lead Consultant are responsible for ensuring the implementation of this guideline within the clinical setting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "All maternity staff are responsible for ensuring they are familiar with this guideline in relation to their practice and have the appropriate skills to implement this guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Recommendations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "All women should undergo a documented assessment of risk factors for VTE in early pregnancy or before pregnancy. All pregnant women should have a documented VTE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "risk assessment at the booking appointment whilst the comprehensive history is being"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "taken. (Refer to Appendix F)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Repeat VTE risk assessment if a patient is admitted to the hospital for any reason or develops other inter-current problems during pregnancy and postpartum period."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "All women require VTE risk assessment following delivery and before discharge; and arrangements made for subcutaneous low molecular weight heparin (LMWH) prescription and administration (usually by the woman herself) in the community where necessary."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "Midwives and doctors should be alert to changes in the woman's situation and be aware that her risk status may change several times during the course of the pregnancy and the postnatal period."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "prefix": 5.5,
                "text": "Body mass index must be calculated at booking visit and documented in the Antenatal Care Record. Obesity remains the most important risk factor for VTE. The revised RCOG guideline (2015) advises weight specific dosage on thromboprophylaxis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix B)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 5.6,
                "text": "Obese women with a body mass index (BMI) of 35 or more are unsuitable for midwife-led care, and should be seen in pregnancy by a consultant obstetrician. (Refer to the guideline entitled \u2018Pregnant patient with a raised body mass index (BMI)'; register number 05092)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "prefix": 5.7,
                "text": "Vulnerable women, such as those with mental illness or learning disability and may not be able to follow advice or self inject, and so require particular care. Antipsychotic medication may be associated with weight gain, which may put the woman at increased risk of thromboembolism."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "prefix": 5.8,
                "text": "Women are at risk of thromboembolism from very early pregnancy until the end of the puerperium, and all health professionals must be aware of this. Early pregnancy units and gynaecology wards must carry out risk assessment appropriate for pregnant women."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "prefix": 5.9,
                "text": "Women with a high or very high risk of VTE should be seen by consultant obstetrician or discussed with consultant obstetrician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Women who require thromboprophylaxis need an individual management plan at all stages of pregnancy. The patient's healthcare records must clearly document dose and duration of treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "prefix": 5.11,
                "text": "Women who are on pharmacological antenatal thromboprophylaxis require anaesthetic referral to discuss individual plans for intrapartum and delivery analgesic options."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "prefix": 5.12,
                "text": "Women who fall into the \u2018very high risk group' require management by a specialist multidisciplinary team including haematologist, obstetrician, midwife and anaesthetist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "prefix": 5.13,
                "text": "Women at high risk of VTE in pregnancy, such as those with previous VTE, should be offered pre-pregnancy counselling and a prospective management plan for thromboprophylaxis in pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "prefix": 5.14,
                "text": "Women who become pregnant before receiving such counselling should be referred to a consultant obstetrician or trust-nominated expert in thrombosis in pregnancy early in pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "prefix": 5.15,
                "text": "Women with a previous non-oestrogen-related VTE provoked by a minor risk factor should undergo testing for thrombophilia, as this will influence management and decisions regarding thromboprophylaxis antenatally."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "prefix": 5.16,
                "text": "Low molecular weight heparins (LMWH) are the agents of choice for antenatal thromboprophylaxis. All pregnant women, at risk of VTE, should be offered Clexane, unless contraindicated. These are at least as effective as and safer than unfractionated heparin."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "prefix": 5.17,
                "text": "The use of aspirin is not recommended for VTE prophylaxis in any patient group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "prefix": 5.18,
                "text": "Regardless of their risk of VTE, all women should be encouraged to mobilise during labour and postpartum. Dehydration should be avoided."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "prefix": 5.19,
                "text": "Elective induction of labour may be indicated in some women (particularly those on high- dose prophylactic or treatment doses of Clexane) to help plan Thromboprophylaxis around delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "Women receiving LMWH antenatally should usually continue prophylactic doses of LMWH until 6 weeks postpartum but a postnatal risk assessment should be made."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "prefix": 5.21,
                "text": "If they are receiving long-term anticoagulation with warfarin, this can be started when the risk of haemorrhage is low from day 7."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "prefix": 5.22,
                "text": "Both warfarin and LMWH are safe when breastfeeding. Women should be repeatedly assessed for risk factors for VTE if they develop intercurrent problems or require surgery or readmission in the puerperium."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "prefix": 5.23,
                "text": "Very high risk women on higher prophylactic dose,anti Xa level is very useful guidance for management of VTE prophylaxis in pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "The timing for the blood test is exactly 4 hours after having Clexane injection otherwise the results are not accurate and cannot be interpreted."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "To book the test in ADVANCE with our laboratory otherwise will be not processed. Eileen Caples and Rejoice Muduwa are our Specialist staff in our laboratory on ext 4137 to be contacted ALWAYS if you are planning to do anti Xa levels."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "Blood forms should have \u2018time of last dose of clexane' and location from where sample was sent to trace back."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "prefix": 5.24,
                "text": "Women on high prophylactic dose of LMWH will need 24 hour following their last dose before they can receive a spinal or epidural. This is obviously different to the 12 hours needed after the normal prophylactic dose. Hence patient should be advised to stop clexane from the evening of planned IOL or Ceasarean section. Patients to be referred to Anaesthetis for advice and plan of management."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Antenatal VTE Risk Assessment and Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "All women should have a documented VTE risk assessment as stated in section 4."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "text": "Those identified at risk should be offered thromboprophylaxis, according to their level of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "text": "risk as defined in this section and the appropriate appendices. Women who commence"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "LMWH should start as soon as possible and within 14 hours of the risk assessment being  completed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "For risk assessment, see flow-chart of risk assessment Appendix F."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 1,
                "text": "Please note obstetric thromboprophylaxis risk assessment and management has been updated in accordance with RCOG Green-Top Guideline 37a April 2015 and the following new information and guidance reflects this."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 1,
                "prefix": 6.3,
                "text": "Very High Risk"
            }
        },
        {
            "type": "table",
            "sequence_num": 67,
            "data": {
                "num_rows": 12,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "One of the following risk factors:"
                    },
                    {
                        "text": "Requires higher-dose LMWH"
                    },
                    {
                        "text": "Prophylaxis dose 12 hourly or weight adjusted 75% of treatment dose"
                    },
                    {
                        "text": "(Refer to Appendix B)"
                    },
                    {
                        "text": "Continue for 6 weeks postpartum or until converted back to Warfarin from Day 7"
                    },
                    {
                        "text": "Seeks obstetric Consultant opinion"
                    },
                    {
                        "text": "Haematology consultant opinion about correct dosage with Anti Xa level"
                    },
                    {
                        "text": "monitoring."
                    },
                    {
                        "text": "Anesthetic referral"
                    },
                    {
                        "text": "Recurrent VTE"
                    },
                    {
                        "text": "Previous recurrent VTE with antiphospholipid antibody syndrome (APS)"
                    },
                    {
                        "text": "Antithrombin III deficiency"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 1,
                "prefix": 6.4,
                "text": "High Risk"
            }
        },
        {
            "type": "table",
            "sequence_num": 69,
            "data": {
                "num_rows": 6,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "One of the following risk factors:"
                    },
                    {
                        "text": "Requires antenatal LMWH prophylaxis"
                    },
                    {
                        "text": "Refer to trust-nominated thrombosis in pregnancy expert/team"
                    },
                    {
                        "text": "Haematology advice"
                    },
                    {
                        "text": "Requires postpartum LMWH for 6 weeks"
                    },
                    {
                        "text": "ANY previous VTE except a single event related to major surgery"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 1,
                "prefix": 6.5,
                "text": "Intermediate risk"
            }
        },
        {
            "type": "table",
            "sequence_num": 71,
            "data": {
                "num_rows": 10,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "One of the following risk factors:"
                    },
                    {
                        "text": "Consider antenatal LMWH prophylaxis (discuss with consultant)"
                    },
                    {
                        "text": "Requires postpartum LMWH after risk assessment"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Hospital admission"
                    },
                    {
                        "text": "Single previous VTE related to major surgery"
                    },
                    {
                        "text": "High risk thrombophilia but no VTE Antiphospholipid syndrome Homozygous Factor V Leiden Homozygous Prothrombin Gene mutation Protein C deficiency Protein S deficiency"
                    },
                    {
                        "text": "Medical comorbidity Cancer Heart failure Active SLE Inflammatory bowel disease Inflammatory polyarthropathy Nephrotic syndrome Type 1 diabetes with nephropathy Sickle cell disease Current intravenous drug users"
                    },
                    {
                        "text": "Any surgical procedure e.g. appendicectomy"
                    },
                    {
                        "text": "Ovarian Hyperstimulation Syndrome"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 1,
                "prefix": 6.6,
                "text": "Generic Risk factors to stratify change in risk"
            }
        },
        {
            "type": "table",
            "sequence_num": 73,
            "data": {
                "num_rows": 10,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Age 35 years and older"
                    },
                    {
                        "text": "Obesity BMI > 30"
                    },
                    {
                        "text": "Low-risk thrombophilia e.g. Heterozygous Prothrombin gene mutation, heterozygous Factor V Leiden"
                    },
                    {
                        "text": "Family history of unprovoked or estrogen-provoked VTE in first degree relative"
                    },
                    {
                        "text": "Parity \u2265 3 (a woman becomes para 3 after her third delivery)"
                    },
                    {
                        "text": "Smoker"
                    },
                    {
                        "text": "Gross varicose veins"
                    },
                    {
                        "text": "Admission or Immobility e.g. Paraplegia, SPD"
                    },
                    {
                        "text": "Current pre-eclampsia"
                    },
                    {
                        "text": "Multiple pregnancy"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "Assisted reproduction techniques"
            }
        },
        {
            "type": "table",
            "sequence_num": 75,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "1 OR 2 RISK FACTORS"
                    },
                    {
                        "text": "LOW RISK"
                    },
                    {
                        "text": "Mobilisation Avoidance of dehydration"
                    },
                    {
                        "text": "3 RISK FACTORS"
                    },
                    {
                        "text": "BECOMES INTERMEDIATE RISK"
                    },
                    {
                        "text": "LMWH prophylaxis from 28 weeks gestation"
                    },
                    {
                        "text": "4 OR MORE RISK FACTORS"
                    },
                    {
                        "text": "BECOMES INTERMEDIATE RISK"
                    },
                    {
                        "text": "LMWH prophylaxis from first trimester"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "prefix": 6.7,
                "text": "Any woman with 3 current risk factors as above should be considered for prophylactic LMWH from 28 weeks gestation and will usually require prophylactic LMWH for 6 weeks postnatally but a postnatal risk assessment should be undertaken by the midwife/ obstetrician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "prefix": 6.8,
                "text": "Any woman with 4 or more current risk factors as above should be treated as intermediate risk and should be considered for prophylactic LMWH from the first trimester and will usually require prophylactic LMWH for 6 weeks postnatally but a postnatal risk assessment should be undertaken by the midwife/ obstetrician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "prefix": 6.9,
                "text": "Women with previous VTE should be offered pre-pregnancy counselling and a prospective management plan for thromboprophylaxis in pregnancy. Those who become pregnant before receiving such counselling should be referred at the earliest opportunity in pregnancy to a clinician with expertise in thrombosis in pregnancy. Women with previous VTE associated with anti-thrombin deficiency should be offered thromboprophylaxis with higher dose LMWH and for 6 weeks postnatally or until returned to oral anticoagulant therapy after delivery. Management should be undertaken in collaboration with a haematologist with expertise in thrombosis in pregnancy and consideration given to antenatal anti-Xa monitoring and the potential for anti-thrombin replacement at initiation of labour or prior to caesarean section."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 1,
                "prefix": 6.1,
                "text": "If objective documentation of previous VTE is not available, the previous history of VTE can be assumed:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "When the woman gives a good history and"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "She received prolonged therapeutic anticoagulation (more than 6 weeks)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 1,
                "prefix": 6.11,
                "text": "Methods for antenatal thromboprophylaxis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 1,
                "text": "Low-molecular-weight heparin"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 1,
                "text": "LMWH's are the agents of choice for antenatal thromboprophylaxis. They are at least as effective as and safer than unfractionated heparin."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 1,
                "text": "Unfractionated heparin"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 1,
                "text": "Unfractionated heparin has a shorter half-life than LMWH and there is more complete reversal of its activity by protamine sulphate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "It may be used in following conditions:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "Around the time of delivery in women at very high risk of thrombosis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "In women at increased risk of haemorrhage;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "In women with renal failure."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 1,
                "text": "Low-dose aspirin"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "The use of aspirin is not recommended for VTE prophylaxis in any patient group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "Aspirin is recommended for all women with antiphospholipid syndrome to improve fetal outcomes. There were no adverse fetal outcomes reported in the trials of low- dose aspirin for prevention of pre-eclampsia in pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 1,
                "text": "Graduated elastic compression stockings"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "Use of properly applied thigh-length stockings are recommended in pregnancy and puerperium but knee-length stockings should be considered if (as is often the case) full-length stockings are ill fitting or compliance is poor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 1,
                "prefix": 6.12,
                "text": "Testing of thrombophilia in women with prior VTE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "The test should be offered if previous VTE was provoked by a temporary minor risk factor (e.g. long distance travel);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "The test is not required for women with a prior unprovoked or estrogen provoked VTE, because obviously, these women should be considered for thromboprophylaxis. The test result would not alter the proposed management."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "It is important to be aware of the effects of pregnancy on the results of thrombophilia tests. In particular, protein S levels are reduced by pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Postpartum VTE Risk Assessment and Thromboprophylaxis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 1,
                "prefix": 7.1,
                "text": "All women require VTE risk assessment following delivery and before discharge; and arrangements made for LMWH prescription and administration (usually by the woman herself) in the community where necessary."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "7.2. For risk assessment, see flow-chart of risk assessment Appendix F."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 1,
                "text": "Please note obstetric thromboprophylaxis risk assessment and management has been updated in accordance with RCOG Green-Top Guideline 37a April 2015 and the following new information and guidance reflects this"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 1,
                "prefix": 7.3,
                "text": "High risk"
            }
        },
        {
            "type": "table",
            "sequence_num": 105,
            "data": {
                "num_rows": 6,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "One of the following risk factors:"
                    },
                    {
                        "text": "Requires at least 6 weeks postnatal prophylactic LMWH"
                    },
                    {
                        "text": "Any previous VTE"
                    },
                    {
                        "text": "Anyone requiring antenatal LMWH"
                    },
                    {
                        "text": "High-risk thrombophilia"
                    },
                    {
                        "text": "Low-risk thrombophilia + Family History of VTE"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 1,
                "prefix": 7.4,
                "text": "Intermediate risk"
            }
        },
        {
            "type": "table",
            "sequence_num": 107,
            "data": {
                "num_rows": 8,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "One of the following risk factors:"
                    },
                    {
                        "text": "Requires at least 10 days postnatal prophylactic LMWH"
                    },
                    {
                        "text": "If persisting or >3 risk factors consider extending course"
                    },
                    {
                        "text": "Caesarean section in labour"
                    },
                    {
                        "text": "BMI > 40 kg/m2"
                    },
                    {
                        "text": "Re-admission or prolonged hospital admission > 3days in the puerperium"
                    },
                    {
                        "text": "Any surgical procedure in the puerperium except immediate repair of perineum"
                    },
                    {
                        "text": "Medical co-morbidity Cancer Heart failure Active SLE Inflammatory bowel disease Inflammatory polyarthropathy Nephrotic syndrome Type 1 diabetes with nephropathy Sickle cell disease Current intravenous drug users"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 1,
                "prefix": 7.5,
                "text": "Generic risk factors to stratify change in risk"
            }
        },
        {
            "type": "table",
            "sequence_num": 109,
            "data": {
                "num_rows": 17,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Age 35 years and older"
                    },
                    {
                        "text": "Obesity (BMI > 30kg/m2)"
                    },
                    {
                        "text": "Family history of VTE"
                    },
                    {
                        "text": "Parity \u2265 3 (a woman becomes para 3 after her third delivery)"
                    },
                    {
                        "text": "Smoker"
                    },
                    {
                        "text": "Elective caesarean section"
                    },
                    {
                        "text": "Pre-term delivery in this pregnancy (<37 weeks)"
                    },
                    {
                        "text": "Stillbirth in this pregnancy"
                    },
                    {
                        "text": "Low-risk thrombophilia"
                    },
                    {
                        "text": "Gross varicose veins"
                    },
                    {
                        "text": "Current systemic infection"
                    },
                    {
                        "text": "Immobility, e.g. paraplegia, SPD, long distance travel"
                    },
                    {
                        "text": "Current pre-eclampsia"
                    },
                    {
                        "text": "Multiple pregnancy"
                    },
                    {
                        "text": "Mid-cavity rotational or operative delivery"
                    },
                    {
                        "text": "Prolonged labour (> 24 hours)"
                    },
                    {
                        "text": "PPH > 1 litre or blood transfusion"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 110,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "1 RISK FACTOR"
                    },
                    {
                        "text": "LOW RISK"
                    },
                    {
                        "text": "Mobilisation Avoidance of dehydration"
                    },
                    {
                        "text": "2 OR MORE RISK FACTORS"
                    },
                    {
                        "text": "BECOMES INTERMEDIATE RISK"
                    },
                    {
                        "text": "At least 10 days postnatal prophylactic LMWH If persisting or >3 risk factors, consider extending course"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "prefix": 7.6,
                "text": "Any woman with 2 current risk factors as above should be given prophylactic LMWH for at least 10 days postpartum, to commence as soon as possible and within 14 hours of the assessment. (NICE 2018)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "prefix": 7.7,
                "text": "All women who have had caesarean sections should be considered for thromboprophylaxis with LMWH for 10 days after delivery apart from those having an elective caesarean section who should be considered for thromboprophylaxis with LMWH for 10 days after delivery only if they have additional risk factors."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "prefix": 7.8,
                "text": "The first thromboprophylactic dose of LMWH should be given as soon as possible after delivery provided that there is no postpartum haemorrhage (but see precautions after use of regional anaesthesia)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "prefix": 7.9,
                "text": "If there has been regional analgesia, in which case LMWH should be given by 4 hours after delivery or 4 hours after removal of the epidural catheter, if it is removed immediately or shortly after delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "If the epidural catheter is left in place after delivery for the purpose of postpartum analgesia, it should be removed 12 hours after a dose and 4 hours before the next dose of LMWH."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "prefix": 7.11,
                "text": "In women who have additional persistent (lasting more than 7 days postpartum) risk factors, such as prolonged admission or wound infection, extend the 7-day period of thromboprophylaxis for up to 6 weeks or until the additional risk factors are no longer present."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 1,
                "prefix": 7.12,
                "text": "Methods for postpartum thromboprophylaxis:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "LMWH is appropriate for postpartum thromboprophylaxis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "text": "Both warfarin and LMWH are safe when breast feeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "text": "If women are receiving long term anticoagulation, warfarin may be preferable,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "text": "Conversion from LMWH to warfarin should be delayed for at least 5\u20137 days after"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "text": "delivery to minimise the risk of haemorrhage during the period of overlap of LMWH"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 0,
                "text": "and warfarin treatment.  (Refer to Management of Women with Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) During Antenatal and Postnatal"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 0,
                "text": "Period; register number 12007)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Staff and Training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "All midwifery and obstetric staff must attend yearly mandatory training which includes skills and drills training."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "All midwifery and obstetric staff are to ensure that their knowledge and skills are up-to- date in order to complete their portfolio for appraisal."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "prefix": 8.3,
                "text": "Guideline Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "text": "8.3.1 As an integral part of the knowledge, skills framework, staff are appraised annually to ensure competency in computer skills and the ability to access the current approved guidelines via the Trust's intranet site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Professional Midwifery Advocates"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "Professional Midwifery Advocates provide a mechanism of support and guidance to women and midwives. Professional Midwifery Advocates are experienced practising midwives who have undertaken further education in order to supervise midwifery services and to advise and support midwives and women in their care choices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Infection Prevention"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "All staff should follow Trust guidelines on infection prevention by ensuring that they effectively \u2018decontaminate their hands' before and after each procedure and when taking   bloods samples to use the Aseptic Non \u2013Touch Technique (ANTT)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "text": "(Hand hygiene; register number 04072)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Audit and Monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "Topics for formal audit are selected on an annual basis in accordance with the requirements the Clinical Audit Strategy and Policy (register number 08076), the Corporate Clinical Audit and Quality Improvement Project Plan and the Maternity Annual Audit Work Plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "prefix": 11.2,
                "text": "Audit of compliance with this guideline will be considered based on national and local audit findings and clinical governance data identifying themes suggesting care delivery is suboptimal. If audit of this guideline is identified as a priority, the Women's and Children's Clinical Audit Group will identify a lead for the audit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 0,
                "prefix": 11.3,
                "text": "The findings of the audit will be reported to and approved by the Women's and Children's Clinical Audit Group and an action plan with named leads and timescales will be developed to address any identified deficiencies. Performance against the action plan will be monitored by this group at subsequent meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 0,
                "prefix": 11.4,
                "text": "Any significant concerns relating to compliance with the requirements of this guideline will be entered on the local Risk Assurance Framework."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "prefix": 11.5,
                "text": "Key findings and learning points from the audit will be submitted to the Clinical Governance Group within the quarterly Women's and Children's Directorate Governance report."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 0,
                "prefix": 11.6,
                "text": "Key findings and learning points will be disseminated to relevant staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "Approval and Implementation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 0,
                "prefix": 12.1,
                "text": "All policies, procedures and guidelines will be circulated clinically and professional approval confirmed by the Asset Owner prior to submission to the Controlled Document team for ratification by the Joint Document Management Group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 0,
                "prefix": 12.2,
                "text": "It is the Guidelines and Audit Nurse's and author's responsibility to inform appropriate Maternity Services' staff of the approved policy documents when they are uploaded to the Trust's Intranets."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "text": "Royal College of Obstetricians and Gynaecologists (2015); Reducing the risk of Venous Thromboembolism during Pregnancy and the Puerperium; Green-top Guideline No. 37a; April. London: RCOG https://www.rcog.org.uk/en/guidelines-research- services/guidelines/gtg37a/"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 0,
                "text": "National Institute of Clinical for Health and Excellence (2012) Venous thromboembolic diseases: NICE clinical guideline (CG 144), June 2012 London: NICE https://www.nice.org.uk/guidance/cg144"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 0,
                "text": "National Institute for Health and Care Excellence (2018) Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE Guideline (NG 89) London: NICE https://www.nice.org.uk/guidance/ng89"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "text": "BJOG An International Journal of Obstetrics and Gynaecology; Centre for Maternal and  Child Enquiries; Saving Mothers' Lives; Reviewing maternal deaths to make motherhood  safer: 2006\u20132008; Volume 118, Supplement 1, March 2011"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 0,
                "text": "Knight M, Bunch K, Tuffnell D, Jayakody H, Shakespeare J, Kotnis R, Kenyon S, Kurinczuk JJ (Eds.) on behalf of MBRRACE-UK. Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2014-16. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2018"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 1,
                "text": "Appendix A"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 1,
                "text": "Low Molecular Weight Heparin"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "text": "A.1 LMWHs are the agents of choice for antenatal thromboprophylaxis. They are at least as"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "text": "effective as and safer than unfractionated heparin."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "text": "A.2 Doses of LMWH for thromboprophylaxis are based on booking weight."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "A.3 Monitoring of anti-Xa levels is not required when LMWH is used for thromboprophylaxis,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "text": "provided that the woman has normal renal function."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 0,
                "text": "A.4 Lower doses of enoxaparin and dalteparin should be employed if the creatinine clearance is"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "text": "less than 30 ml/minute. This would equate to a serum creatinine of about 200 \u03bcmol/ l for a 30-year-old woman weighing 70 kg."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "text": "A.5 A higher prophylactic doses or therapeutic doses of LMWH may be appropriate, in"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "antithrombin deficiency, higher doses of LMWH (weight-adjusted: either 75% or 100% of treatment dose) may be necessary, as judged by anti-Xa levels and monitoring should be by a haemostasis expert"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "A.6 Antenatal period the therapeutic dose should be LMWH- 1mg/kg12 hourly( as documented"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "by RCOG), Daltaparin 100iu/kg12 hourly or Tinzaparin 175iu/kgdaily. (page 21.p 8.1 GTguideline 37a)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 1,
                "text": "Contraindications to LMWH"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "text": "LMWH should be avoided, discontinued or postponed in women who are risk of bleeding after careful consideration of the balance of risks of bleeding and clotting. Risk factors for bleeding are:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "text": "Women with active antenatal or postpartum bleeding;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "text": "Women considered at increased risk of major haemorrhage (such as placenta praevia);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 0,
                "text": "Women with a bleeding diathesis, such as von Willebrand's disease, haemophilia or acquired coagulopathy;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 0,
                "text": "Women with thrombocytopenia (platelet count less than 75 x 109);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 0,
                "text": "Acute stroke in the last 4 weeks (ischaemic or haemorrhagic);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 0,
                "text": "Severe renal disease (glomerular filtration rate less than 30 ml/minute/1.73 m2);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 0,
                "text": "Severe liver disease (prothrombin time above normal range or known varices);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 0,
                "text": "Uncontrolled hypertension (blood pressure greater than 200 mmHg systolic or greater than 120 mmHg diastolic)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 1,
                "text": "Appendix B"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 1,
                "text": "Antenatal and Postnatal Prophylactic Dose of LMWH Weight  Enoxaparin   Dalteparin  Tinzaparin < 50 kg  20 mg  2500 units  3500 units  daily 50\u201390 kg  40 mg  5000 units  4500 units  daily 91\u2013130 kg  60 mg *  7500 unit *   7000 unit *  daily 131\u2013170 kg   80 mg *  10000 unit *   9000 unit *  daily > 170 kg  0.6 mg/kg/day *  75 units/kg/day *  75 units/kg/day *"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 1,
                "text": "High prophylactic (intermediate) dose for very high risk group (for women weighing 50-90 Kg)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 0,
                "text": "40 mg enoxaparin 12-hourly or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 0,
                "prefix": 5000.0,
                "text": "iu dalteparin 12-hourly, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 0,
                "text": "tinzaparin 4500 iu 12-hourly."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 1,
                "text": "Therapeutic dose subcutaneous LMWH (antenatal):"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 0,
                "text": "1 mg/kg enoxaparin 12-hourly or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 0,
                "prefix": 100.0,
                "text": "iu/kg dalteparin 12-hourly or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 0,
                "text": "tinzaparin 175 iu/kg daily."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 184,
            "data": {
                "is_heading": 1,
                "text": "Therapeutic dose subcutaneous LMWH (postnatal):"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 185,
            "data": {
                "is_heading": 0,
                "text": "1.5 mg/kg enoxaparin daily or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 186,
            "data": {
                "is_heading": 0,
                "text": "200 u/kg dalteparin daily or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 0,
                "text": "tinzaparin 175 u/kg daily."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 1,
                "text": "*may be given in two divided doses"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 1,
                "text": "Appendix C"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 1,
                "text": "Unfractionated Heparin"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 0,
                "text": "Unfractionated heparin has a shorter half-life than LMWH and there is more complete reversal of its activity by protamine sulphate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 192,
            "data": {
                "is_heading": 0,
                "text": "It may be used in following conditions:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 0,
                "text": "Around the time of delivery in women at very high risk of thrombosis (when there may be reluctance to use LMWH in case regional anaesthetic techniques are required;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 194,
            "data": {
                "is_heading": 0,
                "text": "In women at increased risk of haemorrhage;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 0,
                "text": "In women with renal failure."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 196,
            "data": {
                "is_heading": 0,
                "text": "A prophylactic dose of 5000 iu subcutaneously of unfractionated heparin could be used and repeated every 12 hours until LMWH can be resumed after delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 197,
            "data": {
                "is_heading": 0,
                "text": "The required interval between a prophylactic dose of unfractionated heparin and regional analgesia or anaesthesia is less (4 hours) than with LMWH (12 hours)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 198,
            "data": {
                "is_heading": 0,
                "text": "There is less concern regarding neuraxial haematomas with unfractionated heparin."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 199,
            "data": {
                "is_heading": 0,
                "text": "Any exposure to unfractionated heparin is associated with an increased risk of heparin induced thrombocytopenia."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 200,
            "data": {
                "is_heading": 1,
                "text": "Appendix D"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 201,
            "data": {
                "is_heading": 1,
                "text": "Graduated Elastic Compression Stockings"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 202,
            "data": {
                "is_heading": 0,
                "text": "Use of properly applied thigh-length stockings are recommended in pregnancy and puerperium but knee-length stockings should be considered if (as is often the case) full-length stockings are ill fitting or compliance is poor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 203,
            "data": {
                "is_heading": 0,
                "text": "Indications for anti-embolism stockings in pregnancy and the puerperium"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 204,
            "data": {
                "is_heading": 0,
                "text": "Those who are hospitalised and have a contraindication to LMWH;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 205,
            "data": {
                "is_heading": 0,
                "text": "Those who are hospitalised post-caesarean section (combined with LMWH) and considered to be at particularly high risk of VTE (such as previous VTE, more than three 3 risk factors);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 206,
            "data": {
                "is_heading": 0,
                "text": "Outpatients with prior VTE (usually combined with LMWH);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 207,
            "data": {
                "is_heading": 0,
                "text": "Travelling long distance for more than 4 hours;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 208,
            "data": {
                "is_heading": 0,
                "text": "Symptomatic DVT, patients should wear a tighter-fitted stocking during the day, with an ankle pressure gradient of 30\u201340 mmHg for 2 years to prevent the post-thrombotic; syndrome (and continue for longer if post-thrombotic symptoms are present)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 209,
            "data": {
                "is_heading": 0,
                "text": "Do not offer anti-embolism stockings to patients who have:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 210,
            "data": {
                "is_heading": 0,
                "text": "Suspected or proven peripheral arterial disease;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 211,
            "data": {
                "is_heading": 0,
                "text": "Peripheral arterial bypass grafting;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 212,
            "data": {
                "is_heading": 0,
                "text": "Peripheral neuropathy or other causes of sensory impairment;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 213,
            "data": {
                "is_heading": 0,
                "text": "Any local conditions in which stockings may cause damage, for example fragile \u2018tissue paper' skin, dermatitis, gangrene or recent skin graft;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 214,
            "data": {
                "is_heading": 0,
                "text": "Known allergy to material of manufacture;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 215,
            "data": {
                "is_heading": 0,
                "text": "Cardiac failure;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 216,
            "data": {
                "is_heading": 0,
                "text": "Severe leg oedema or pulmonary oedema from congestive heart failure;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 217,
            "data": {
                "is_heading": 0,
                "text": "Unusual leg size or shape;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 218,
            "data": {
                "is_heading": 0,
                "text": "Major limb deformity preventing correct fit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 219,
            "data": {
                "is_heading": 0,
                "text": "Use caution and clinical judgement when applying anti-embolism stockings over venous ulcers or wounds."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 220,
            "data": {
                "is_heading": 0,
                "text": "Ensure that patients who develop oedema or postoperative swelling have their legs re-measured and anti-embolism stockings refitted. Use anti-embolism stockings that provide graduated compression and produce a calf pressure of 14\u201315 mmHg."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 221,
            "data": {
                "is_heading": 0,
                "text": "Encourage patients to wear their anti-embolism stockings day and night until they no longer have significantly reduced mobility."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 222,
            "data": {
                "is_heading": 0,
                "text": "Remove anti-embolism stockings daily for hygiene purposes and to inspect skin condition. In patients with a significant reduction in mobility, poor skin integrity or any sensory loss, inspect the skin two or three times per day, particularly over the heels and bony prominences."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 223,
            "data": {
                "is_heading": 0,
                "text": "Discontinue the use of anti-embolism stockings if there is marking, blistering or discolouration of the skin, particularly over the heels and bony prominences, or if the patient experiences pain or discomfort. If suitable, offer a foot impulse or intermittent pneumatic compression device as an alternative."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 224,
            "data": {
                "is_heading": 1,
                "text": "Appendix E"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 225,
            "data": {
                "is_heading": 1,
                "text": "Assessment of Bleeding Risk"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 226,
            "data": {
                "is_heading": 0,
                "text": "Assess all patients for risk of bleeding before offering pharmacological VTE prophylaxis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 227,
            "data": {
                "is_heading": 1,
                "text": "Do not offer pharmacological VTE prophylaxis to patients with any of the risk factors for bleeding shown below, unless the risk of VTE outweighs the risk of bleeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 228,
            "data": {
                "is_heading": 0,
                "text": "Women at high risk of haemorrhage may be more conveniently managed with unfractionated heparin or graduated compression stockings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 229,
            "data": {
                "is_heading": 0,
                "text": "If a woman develops a haemorrhagic problem while on LMWH, the treatment should be stopped and expert haematological advice sought."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 230,
            "data": {
                "is_heading": 0,
                "text": "It should be remembered that excess blood loss and blood transfusion is a risk factor for VTE, so thromboprophylaxis should be begun or reinstituted as soon as the immediate risk of haemorrhage is reduced."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 231,
            "data": {
                "is_heading": 0,
                "text": "For women with an identified bleeding risk, the balance of risks of bleeding and clotting should be discussed in consultation with a haematologist with experience of thrombosis and bleeding in pregnancy."
            }
        },
        {
            "type": "table",
            "sequence_num": 232,
            "data": {
                "num_rows": 10,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Risk factors of bleeding"
                    },
                    {
                        "text": "Haemophilia or other known bleeding disorder (e.g. von Willebrand's disease or acquired coagulopathy)"
                    },
                    {
                        "text": "Active antenatal or postpartum bleeding"
                    },
                    {
                        "text": "Women considered at increased risk of major haemorrhage (e.g. placenta praevia)"
                    },
                    {
                        "text": "Thrombocytopenia (platelet count < 75 \u00d7109)"
                    },
                    {
                        "text": "Acute stroke in previous 4 weeks (haemorrhagic or ischaemic)"
                    },
                    {
                        "text": "Severe renal disease (glomerular filtration rate < 30 ml/minute/1.73 m2)"
                    },
                    {
                        "text": "Severe liver disease (prothrombin time above normal range or known varices)"
                    },
                    {
                        "text": "Uncontrolled hypertension (blood pressure > 200 mmHg systolic or > 120 mmHg diastolic)"
                    },
                    {
                        "text": "Concurrent use of anticoagulants (such as warfarin with INR higher than 2)"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 233,
            "data": {
                "is_heading": 1,
                "text": "Appendix F"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 234,
            "data": {
                "is_heading": 1,
                "text": "Risk Assessment for VTE Antenatal Notes"
            }
        },
        {
            "type": "image",
            "sequence_num": 235,
            "data": {
                "url": "08014B VTE risk assessment  thrombophylaxis in maternity 6.2.003.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 236,
            "data": {
                "is_heading": 1,
                "text": "Risk Assessment for VTE Labour Care Notes"
            }
        },
        {
            "type": "image",
            "sequence_num": 237,
            "data": {
                "url": "08014B VTE risk assessment  thrombophylaxis in maternity 6.2.003.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 238,
            "data": {
                "is_heading": 1,
                "text": "Risk Assessment for VTE Postnatal Maternal Notes"
            }
        },
        {
            "type": "image",
            "sequence_num": 239,
            "data": {
                "url": "08014B VTE risk assessment  thrombophylaxis in maternity 6.2.004.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 240,
            "data": {
                "is_heading": 0,
                "text": "VTE in Maternity/08014B/6.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 241,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 242,
            "data": {
                "is_heading": 1,
                "text": "Appendix G"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 243,
            "data": {
                "is_heading": 1,
                "text": "Appendix H: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 244,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Venousthromboembolism (VTE) Risk Assessment and Thromboprophylaxis in Maternity/ 08014B"
            }
        },
        {
            "type": "table",
            "sequence_num": 245,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Full Review"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "3 year review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Yes; Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 246,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 247,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Anita Dutta"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Consultant Obstetrician"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "June 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 248,
            "data": {
                "is_heading": 0,
                "text": "VTE in Maternity/08014B/6.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 249,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        }
    ]
}